Overview

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-12-20

Target enrollment:

Participant gender:

Summary

The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Tao Jiang

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel